Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

Stock Information for Minerva Neurosciences Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Minerva Neurosciences Inc

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.